| Literature DB >> 33536277 |
Wayne C Koff1,2, Theodore Schenkelberg3,2, Tere Williams4, Ralph S Baric5, Adrian McDermott6, Cheryl M Cameron7, Mark J Cameron7, Matthew B Friemann8, Gabriele Neumann9, Yoshihiro Kawaoka9,10, Alyson A Kelvin11, Ted M Ross12, Stacey Schultz-Cherry13, Timothy D Mastro14, Frances H Priddy15, Kristine A Moore16, Julia T Ostrowsky16, Michael T Osterholm16, Jaap Goudsmit3,17.
Abstract
Development of safe and effective COVID-19 vaccines is a global priority and the best hope for ending the COVID-19 pandemic. Remarkably, in less than 1 year, vaccines have been developed and shown to be efficacious and are already being deployed worldwide. Yet, many challenges remain. Immune senescence and comorbidities in aging populations and immune dysregulation in populations living in low-resource settings may impede vaccine effectiveness. Distribution of vaccines among these populations where vaccine access is historically low remains challenging. In this Review, we address these challenges and provide strategies for ensuring that vaccines are developed and deployed for those most vulnerable.Entities:
Mesh：
Substances：
Year: 2021 PMID： 33536277 DOI： 10.1126/scitranslmed.abd1525
Source DB: PubMed Journal: Sci Transl Med ISSN： 1946-6234 Impact factor: 17.956